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Background: A significant proportion of patients undergoing radical nephrectomy (RN) for clear-cell renal cell carcinoma (RCC)
develop chronic kidney disease (CKD) within a few years following surgery. Chronic kidney disease has important health, social
and economic impact and no predictive biomarkers are currently available. MicroRNAs (miRs) are small non-coding RNAs
implicated in several pathological processes.
Methods: Primary objective of our study was to define miRs whose deregulation is predictive of CKD in patients treated with RN.
Ribonucleic acid from formalin-fixed paraffin embedded renal parenchyma (cortex and medulla isolated separately) situated
43 cm from the matching RCC was tested for miR expression using nCounter NanoString technology in 71 consecutive patients
treated with RN for RCC. Validation was performed by RT–PCR and in situ hybridisation. End point was post-RN CKD measured 12
months post-operatively. Multivariable logistic regression and decision curve analysis were used to test the statistical and clinical
impact of predictors of CKD.
Results: The overexpression of miR-193b-3p was associated with high risk of developing CKD in patients undergoing RN for RCC
and emerged as an independent predictor of CKD. The addition of miR-193b-3p to a predictive model based on clinical variables
(including sex and estimated glomerular filtration rate) increased the sensitivity of the predictive model from 81 to 88%. In situ
hybridisation showed that miR-193b-3p overexpression was associated with tubule-interstitial inflammation and fibrosis in patients
with no clinical or biochemical evidence of pre-RN nephropathy.
Conclusions: miR-193b-3p might represent a useful biomarker to tailor and implement surveillance strategies for patients at high
risk of developing CKD following RN.
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Renal clear-cell carcinoma (RCC) is the most common type of
kidney tumour in adults (85%) and accounts for 3% of all
malignancies (Ferlay et al, 2013; Siegel et al, 2016). Surgery
represents the gold standard for the treatment of clinically localised
RCC (Ljungberg et al, 2015). Although oncological outcomes (in
tumours measuring o4 cm) are similar in radical nephrectomy
(RN) and in nephron sparing surgery (NSS), the incidence of long-
term morbidity due to the development of chronic kidney disease
(CKD) is higher in the case of RN due to the loss of nephron mass
(Capitanio et al, 2016). Chronic kidney disease affects quality of life
and life expectancy and has important health-economic implica-
tions being associated with increased cardiovascular risk, metabolic
syndromes and end-stage kidney disease (Nashar and Egan, 2014).
Even though several mechanisms for the decay in renal function
following RN have been hypothesised, no predictive markers are
currently available to inform clinicians of the risk of developing
CKD and to tailor surveillance and secondary prevention programs
(Capitanio et al, 2016).
MicroRNAs (miRs) are short (19–24 nucleotides) non-protein
coding RNAs fine tuning cell homeostasis by controlling gene
expression at post-transcriptional level (Fabbri et al, 2009; Winter
et al, 2009). MicroRNAs are implicated in renal physiology
regulating ion transport, electrolytes and acid–base equilibrium, as
well as blood pressure (Elvira-Matelot et al, 2010; Mladinov et al,
2013; Trionfini et al, 2015). MicroRNAs deregulation is common
to many cancers as well as infectious, cardiovascular, metabolic and
kidney diseases and it can be exploited for screening, diagnosis and
treatment (Catto et al, 2011; Mendell and Olson, 2012; Fasanaro
et al, 2015; Trionfini et al, 2015).
In the current study, we aimed to test miR deregulation in
‘normal’ kidney tissue in patients with and without deterioration in
renal function after RN for RCC, in order to define predictive
biomarkers of CKD.
MATERIALS AND METHODS
Study population. One-hundred and five patients treated with
RN for RCC at San Raffaele Hospital (Milan, Italy) between 2008
and 2013 were eligible for the study. The project has been approved
by the relevant Ethic Committee (approval 2007/29082007/V3)
and informed consent is available for each patient. The inclusion
criteria of the study were: (a) age 418 and o80 years; (b) clear-
cell carcinoma histology; (c) resectable RCC and absence of
metastatic within the initial 12 months from diagnosis; (d) no
history of other malignancies; (e) normal renal function prior to
RN, estimated glomerular fraction rate (eGFR)460mlmin 1
(CKD-EPI formula 2009 (Eknoyan et al, 2013)), serum creatinine
o1.1mg dl 1 and no urinary abnormalities (i.e., proteinuria);
(f) absence of primitive, secondary, hereditary or acquired
glomerulopathies; (g) absence of kidney stone disease, myelopro-
liferative disorders and autoimmune diseases (i.e., vasculitis and
systemic infections); (h) absence of chronic nephrotoxic drug
therapy (e.g., lithium, NSAID). All patients underwent post-
operative review 1 month after RN and 6-month follow-up with
physical examination, lab test and CT scan thereafter.
Twelve renal biopsies (cortex only) from kidney donors
(Remuzzi score p4 (Remuzzi et al, 1999)) were collected from
the archives of the Surgical Pathology Unit at Padua University
(Padua, Italy) and used as controls (Ethic Committee approval
#: 0011418–02/03/2015).
Pathology review. Haematoxylin and eosin-stained slides from
100 formalin-fixed paraffin-embedded tissues were reviewed by a
pathologist. Only samples 43 cm distance from RCC were
considered. Renal cortex and medulla were manually micro-
dissected in order to separate the glomerular region from the loop
of Henle and collecting ducts. Twenty cases were excluded due to
inadequate representation of the cortex region (o10 glomeruli on
 10 field of view), because this might have impaired the yield of
RNA from the glomeruli.
Total RNA extraction was performed using Ambion Recover All
Isolation Kit (Life Technologies, Carlsbad, CA, USA), according to
the manufacturer’s instructions. The purity and quality of extracted
RNA was determined by Bio-Analyser (Agilent Technologies,
Santa Clara, CA, USA). Nine samples were discarded due to poor
RNA purity/quality.
NanoString nCounter and bioinformatics analysis. MicroRNA
expression was analysed using the nCounter Human v2 miR
Expression Assay kit (NanoString, Seattle, WA, USA) as we
previously described (Valeri et al, 2014). This assay detects 800
endogenous miRs, 5 housekeeping transcripts plus 6 positive and 6
negative controls. About 150 ng of each total RNA sample was used
as input into the nCounter Human miR sample preparation.
Hybridisation was conducted for 16 h at 65 1C. Subsequently, the
strip tubes were placed into the nCounter Prep Station for
automated sample purification and subsequent reporter capture.
Each sample was scanned for 555 fields of view on the nCounter
Digital Analyzer (NanoString). Data were extracted using the
nCounter RCC Collector (NanoString). Two samples, one medulla
from a patient with normal kidney function (NKF) and one cortex
from a healthy kidney donor, failed quality control and were
excluded from further analysis.
Raw data, which are proportional to copy number, were log-
transformed and normalised by the quantile method after
application of a manufacturer-supplied correction factor for several
miR (Cascione et al, 2013). Data were filtered to exclude relatively
invariant features (IQR¼ 0.5) and features below the detection
threshold (defined for each sample by a cutoff corresponding to
B2 s.d. of negative control probes plus the mean of them) in at
least half of the samples. After the pre-processing steps described
above, we plotted the relative differences in transcriptional profile
between the samples using multidimensional scaling plot. Using
R/Bioconductor and the filtered data set, significance analysis of
microarrays was employed with a contrast matrix for the
comparisons (Cascione et al, 2013). P-values were used to rank
miRs of interest, and correction for multiple comparisons was
performed using the Benjamini–Hocheberg method (Benjamini
and Hochberg, 1995). Raw data that were above background, as
well as the corresponding quantile-normalised data, were imported
into MultiExperiment Viewer (http://mev.tm4.org/) for visual
inspection.
Heatmaps were generated using the Euclidean distance as metric
distance and a single clustering as linkage criterion. Only miRs
with a t-test P-value o0.1 were included in the heatmaps. The
colour red indicates strong expression of a miR, whereas a blue
point mirrors a reduced level of a determined miR.
MicroRNA expression data have been submitted to GEO under
accession number GSE80247.
RT–PCR analysis. Expression of four of the most importantly
dysregulated miRs detected using NanoString nCounter Analysis
(hsa-miR-193b-3p, hsa-miR-365a-3p, hsa-miR-363b-3p and hsa-
miR-139b-5p) was investigated by RT–PCR using Taqman assays
(Life Technologies). Comparative RT–PCR was run in triplicate,
including no template controls and endogenous control gene
RNU48. The fold difference for each sample was obtained using the
DCT method.
miR-193b in situ hybridisation analysis. Locked nucleic acid
(LNA) probes with complementarity to miR-193b-3p were labelled
with 50-biotin and synthesised using Exiqon (Vedbaek, Denmark).
Tissue sections were digested with ISH protease 1 (Ventana
Medical Systems, Milan, Italy) and ISH was performed as we
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previously described (Nuovo et al, 2012). Positive (U6; Exiqon) and
negative scrambled LNA probes (Exiqon) were used as controls.
Only cytoplasmic miR staining was retained for scoring purposes.
Statistical analyses. The end point of the study was the rate of
de novo post-RN CKD defined as stage 3a-3b-4 calculated 12
months after surgery (Eknoyan et al, 2013).
First, the Mann–Whitney test was used to compare the
statistical significance of differences in the distribution of each
miR of interest according to CKD. Second, multivariable logistic
regression analysis (MVA) was used to construct a baseline model
predicting the CKD relying on clinical predictors only. Such
predictors were factors suggestive for increased risk of post-surgical
CKD, and consisted of age, gender, baseline eGFR, clinical tumour
size (defined as the largest tumour dimension at preoperative
imaging) and presence of diabetes. Third, each miR of interest was
independently added to the baseline model, and the concordance
index of each miR-inclusive model was compared with that of the
baseline model. Fourth, the net benefit of the baseline model and of
each miR-inclusive model was assessed using decision curve
analysis (Vickers and Elkin, 2006).
RESULTS
Baseline clinical characteristics and measure of clinical out-
come. Of the originally collected one-hundred and five patients
with histologically proven, RCC treated with curative RN, 71
patients were included in our study for clinical and molecular
predictors of CKD (34 patients were excluded from the analysis
and details are shown in Figure 1). Patient characteristics are
summarised in Table 1.
Fourteen (20%) patients suffered from type II diabetes control
by oral hypoglycaemic agents at the time of diagnosis; no patients
had type I diabetes (Table 1). Histological review of resection
specimen ruled out signs of pre-existing nephropathy in all these
patients. Similarly, none of the patients showed biochemical signs
of CKD with normal renal function in the absence of proteinuria.
Physiological fluctuations in the eGFR are common in the post-
RN setting, relate to compensatory nephron hyperfiltration in the
contralateral kidney and, usually, occur within the initial 6 months
from the operation. Given that several lines of evidence suggest
that a reduction in eGFR at 12 months from RN is associated with
increased risk of CKD (Westland et al, 2014), our end point
measurement was performed 12 months post RN.
Thirty-eight (54%) patients experienced a reduction in eGFR,
developing a mild to severe CKD 12 months post RN.
(Supplementary Figure S1A and 1B).
Identification of microRNAs associated with CKD in the
training cohort. In order to define miRs discriminating patients
who developed CKD at 12 months post RN and patients with NKF,
we performed miR expression analysis in a randomly selected
training cohort of 12 CKD and 12 NKF patients. As CKD can be
related to different abnormalities affecting the nephron, the cortex
and medulla were dissected and tested for miR expression
separately.
Nine miRs were upregulated and one was downregulated
41.5-fold (P-value p0.05) in the comparison between CKD and
NKF patients (irrespective of the anatomic location) (Supplementary
Table S1).
When the analysis compared the medulla of CKD and NKF
patients, ten miRs were found to be overexpressed more than
1.5-fold in CKD patients. No miR showed statistically significant
downregulation41.5-fold (Figure 2 and Supplementary Table S2).
Conversely, when the analysis focused on the cortex, two miRs
were found to be upregulated and one miR was downregulated
41.5-fold in CKD patients (Supplementary Figure S2 and
Supplementary Table S3).
Shortlisting and validation of miRs found to be deregulated in
CKD vs NKF patients. For the validation of miRs associated with
the development of CKD, we focused on miRs upregulated in the
comparison between medulla of CKD vs NKF patients based on the
following observations: (1) CKD is largely due to early tubular
dysfunction, which promotes increased sodium reabsorption and
glomerular hyperfiltration (Capitanio et al, 2016); (2) the
comparison between medulla of CKD vs NKF provided more
significantly deregulated miRs than the comparison between cortex
of the same patients; (3) overexpressed rather than silenced miRs
might be easier to detect in tissues and biological fluids.
Expression of the four miRs (miR-193b-3p, miR-365a-3p, miR-
363b-3p and miR-139b-5p) deregulated in the medulla of CKD vs
NKF patients detected in the training cohort by nCounter was
confirmed in the same cohort (n¼ 23) and validated in the
remaining patients (n¼ 47) by RT–PCR. All four miRs were
confirmed as significantly upregulated in the cortex of CKD
patients (Supplementary Table S4).
Clinical and molecular predictors of CKD. In order to define
clinical markers of CKD we performed a MVA, which showed that
gender (odds ratio (OR) 6.07; P¼ 0.02) and preoperative eGFR
(OR 0.93; P¼ 0.02) are independent predictors of CKD
(base model (Table 2)). The area under the curve (AUC) of the
base model was 81%. When each miR was included in the base
model, each miR emerged as an independent predictor of CKD
after adjustment for clinical variables. Specifically, miR-193b-3p
(OR 2.28; P¼ 0.002), miR-363b-3p, (OR 6.28; P¼ 0.04), miR-
139b-5p (OR 5.86; P¼ 0.01) and miR-365a-3p (OR 2.18; P¼ 0.01)
were all associated with an increased risk of CKD. Moreover, after
the inclusion of miR-193b-3p, miR363b-3p, miR139b-5p and
miR365a-3p, the AUC of the base model increased to 88%, 83%,
86% and 86%, respectively (Table 2). At decision curve analyses
(DCA), the inclusion of each miR into a baseline model predicting
CKD using only clinical variables yielded a higher net benefit
(Figure 3). In order to test whether the inclusion of multiple miRs
to the basic model would yield higher predictive value, we selected
model 1 (Table 2) as our base model (clinical-pathological
variablesþmiR-193b-3p) and we added miR-363b-3p, miR-
139b-5p and miR-365a-3p expression individually. None of these
miRs increased the clinical and/or statistical power of the
predictive model including miR-193b-3p alone (all P40.05).
Moreover, the inclusion of miR-363b, miR-139b and miR-365a
in such model was associated with an AUC of 0.88, 0.89 and 0.89,
respectively, which do not differ from the AUC of our original
model 1 including clinical-pathological parametersþmiR-193b
expression (0.88). On the basis of these observations, we focused
our attention on miR-193b-3p alone for further analysis.
MiR-193b-3p tissue of origin. MicroRNA expression is organ
and tissue dependent (Lim et al, 2005). In order to validate the
observations gathered from nCounter and RT–PCR data and
provide insights in the role of these miRs in CKD pathogenesis, we
performed miR-193b-3p ISH analysis in medulla and cortex tissues
in samples characterised by high and low miR-193b-3p expression
at nCounter and RT–PCR analysis in patients with high
preoperative eGFR.
In cases with low miR-193b-3p expression, faint miR-193b-3p
staining was observed in the collector ducts (medulla), distal
convoluted tubule and glomerular endothelial cells (cortex). High-
miR-193b-3p cases were characterised by strong miR expression in
the inflammatory infiltrate and in fibroblasts present in both renal
regions. Moreover, in keeping with the nCounter expression data,
significant miR-193b-3p overexpression was observed in atrophic
and swollen tubules and in ducts within the medulla (Figure 4).
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Cancer can cause re-wiring of miR and gene expression in
adjacent surrounding tissues (Volinia et al, 2010). In order to test
whether miR-193b-3p expression changes in renal parenchyma
were caused by the cancer, we compared global miR expression in
patients who underwent RN for RCC with healthy kidney donors.
Even though a global miR deregulation was observed in ‘normal’
tissues surrounding cancer compared with healthy donors, miR-
193b-3p was not among the deregulated miRs (Supplementary
Figures S3 and S4 and Supplementary Table S5). To support this
observation, we also analysed miR-193b-3p expression in RCC
patients in The Cancer Genome Atlas (TCGA (Cancer Genome
Atlas Research N, 2013)) data set for whom cancer and matching
normal miR-Seq data were available. Comparison of cancer and
adjacent tissues confirmed that miR-193b-3p is overexpressed by
40% (Po0.0001) in normal tissues adjacent to the cancer
(Supplementary Figure S5).
DISCUSSION
Three quarters of patients affected by stage I–II RCC will survive
more than 5 years from the initial diagnosis (Karakiewicz et al,
2007). Although several efforts to improve oncological outcome in
early and metastatic RCC patients are ongoing, little has been done
to reduce comorbidities and improve quality of life and outcome in
cancer survivors.
The incidence of CKD is increasing worldwide and the
association between RN and increased risk of CKD is well
documented (Mariusdottir et al, 2013), highlighting the unmet
need for predictive biomarkers that might enable us to tailor
patients’ surveillance and treatment.
MiR deregulation has been studied in RCC and diabetes-related
kidney disorders (Catto et al, 2011; Trionfini et al, 2015), but no
study has linked miR deregulation with the risk of developing CKD
in RN patients.
Our study led to two main conclusions: (1) the use of miR-193b-
3p improves the predictive value of clinical nomograms in
estimating the risk of CKD; (2) miR-193b-3p upregulation is
associated with morphological features of inflammation, fibrosis
and atrophy in patients with no preoperative clinical or
biochemical evidence of kidney disease.
Our data rely on the retrospective analysis of a limited cohort of
patients, thus are not intended to change clinical practice.
However, while prospective validation studies are ongoing,
questions and avenues of future research have arisen.
Inclusion criteria
•   Age >18 and < 80 years
•   Clear cells carcinoma histology 
•   Resectable RCC and absence of metastatic disease 
•   Normal renal function prior to RN*
Exclusion criteria
•   History of other malignancies and/or myeloproliferative disorders
•   History of primitive or secondary, hereditary or acquired glomerulopathies
•   History kidney stone disease, autoimmune diseases
•   Chronic use of nephrotoxic drugs therapies (i.e., lithium, NSAID) 
105 consecutive patients treated with radical nephrectomy for clear
cell renal carcinoma at San Raffaele Hospital between 2008 and 2013
Sixteen patients excluded due
to <10 glomeruli on histology
review
Nine patients excluded due to
poor RNA quality
microRNA expression analysis using nCounter NanoString analysis cortex and medulla from: 
- 12 patients who developed CKD
- 12 patients who did not develop CKD
- 12 healthy kidney donors
miR-193b-3p RT-PCR analysis in training  (n=24) and validation (n=47) cohorts
miR-193b-3p analysis by ISH in
miR-193b-3p high (n=5) and miR-193b-3p low (n=5) cases 
Nine patients excluded due
to metastatic disease within the
initial 12 months post-RN
Figure 1. Schematic overview of the study. *The eGFR460mlmin 1 based on CKD-EPI formula 2009. CKD, chronic kidney disease; eGFR,
estimated glomerular fraction rate; ISH, in situ hybridisation; RN, radical nephrectomy.
Table 1. Descriptive characteristics of 71 patients treated
with radical nephrectomy for kidney cancer
Variable Overall
Age, years
Median 65
IQR 55–71
Gender
Male 50 (70.4)
Female 21 (30.6)
Preoperative eGFR, mlmin1
Median 90
IQR 78–97
Tumour size, mm
Median 65
IQR 53–80
Kidney dimension, mm
Median 125
IQR 110–145
Diabetes
No 57 (80.2)
Yes 14 (20.8)
Abbreviations: eGFR¼estimated glomerular fraction rate; IQR¼ interquartile range. Data are
presented as frequencies and percentages (numbers in brackets) unless otherwise specified.
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miR-3151
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miR-487b
miR-215
miR-379-50
miR-337-5p
miR-652-3p
miR-532-3p
miR-33a-5p
miR-193a-3p
miR-514b-5p
miR-484
miR-455-3p
miR-331-3p
miR-182-5p
miR-183-5p
miR-2682-5p
miR-363-5p
miR-139-3p
miR-139-5p
miR-151a-5p
miR-19b-3p
miR-374b-5p
miR-140-5p
miR-195-5p
miR-374a-5p
miR-660-5p
miR-324-5p
miR-28-5p
miR-146a-5p
miR-181b-5p miR-181d
miR-342-3p
miR-15b-5p
miR-24-3p
miR-223-3p
miR-489
miR-150-5p
miR-1260a
miR-204-5p
miR-200c-3p
miR-30d-5p
miR-130a-3p
let-7d-5p
miR-196a-5p
miR-4286
miR-4454
miR-30a-5p
miR-720
let-7a-5p
miR-30b-5p
miR-135a-5p
miR-143-3p
miR-186-5p
NKF
CKD
–3.0
–2.4
–1.8
–1.2
–0.6
0.0
+0.5
+1.0
+1.5
+2.0
+2.5
+3.0
Figure 2. Heatmap showing miR expression in medulla of patients with normal kidney function (NKF) compared with patients developing
chronic kidney disease (CKD) 12 months post nephrectomy for RCC. The miRs with a P-value p0.1 are shown.
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MiR-193b-3p has been previously characterised as a regulator of
transcription factors such as MYB (Mets et al, 2015), downstream
effector of MAPK (Ikeda et al, 2012) pathway and regulator of cell
steaminess (Haetscher et al, 2015) in different tumour types
including pancreatic cancers and leukaemia. Similarly, miR-193b-
3p dysregulation has been detected in rheumatic disorders
(Iwamoto et al, 2016), pre-eclampsia (Xu et al, 2014), as well as
inflammation in white adipose tissues (Arner et al, 2012) through
the regulation of inflammatory chemokines.
In our cohort, miR-193b-3p overexpression is associated with
inflammation and atrophy and can be detected in tubular, ductal
and inflammatory cells suggesting crosstalk between different
compartments in promoting inflammation and fibrosis.
A reasonable question is whether the cancer is promoting
inflammatory changes and miR-193b-3p overexpression. It is
worth noticing that miR-193b-3p upregulation was independent of
tumour and/or kidney size and no evidence of compression from
the cancer was observed on histological review, excluding an
indirect effect of malignancy in promoting an inflammatory/
hypoxic reaction in the normal counterpart. Exosome transfer of
miR has been widely studied in the interaction between tumour
and its surrounding tissues (Neviani and Fabbri, 2015), thus it is
legitimate to speculate that overexpression of miR-193b-3p in
cancer could have driven the phenotype we observed. Some
observations, however, argue against this theory, as the analysis of
an independent cohort of RCC cases and matching controls
included in the TCGA data set revealed a downregulation of miR-
193b-3p in cancer compared with normal tissues; an observation
that fits with several reports suggesting a tumour suppressor role
for miR-193b-3p (Gastaldi et al, 2014; Mets et al, 2015). Further
evidence supporting this hypothesis is represented by the
comparison of RCC-matched normal tissues vs healthy kidney
donors. Even though a general re-wiring of miR expression,
possibly due to the cancer microenvironment, was observed, miR-
193b-3p was not found to be deregulated in this comparison,
suggesting that its upregulation might be independent from cancer.
A MVA for CKD suggested that basal eGFR was an independent
predictor of CKD; however, even patients with high basal eGFR
experienced a pathological reduction in glomerular filtration. As
suggested by ISH analysis these patients showed early morpholo-
gical signs of tubular-glomerular sclerosis associated with miR-
193b-3p upregulation providing an explanation for the improved
predictive value of the DCA when both parameters were included.
Similar to our observations, miR-193b-3p has been found to be
upregulated in tissues and urine in patients with kidney interstitial
fibrosis, tubular atrophy and acute kidney rejection, suggesting that
this miR might be involved in pro-inflammatory feedback
involving the interstitial compartment (Wilflingseder et al, 2013;
Maluf et al, 2014).
The observation that miR-193b-3p upregulation appears
independent from the cancer microenvironment and common to
other inflammatory tubular-interstitial nephropathies led us to
speculate that it might be indicative of a pre-existing, clinically and
biochemically undetectable, disease potentially also affecting the
contralateral kidney. In this scenario, the acute loss of nephron
mass caused by nephrectomy could trigger hyperfiltration
mechanisms, which in the presence of tubular atrophy and fibrosis
in the remaining kidney could irreversibly compromise the
tubular-glomerular feedback. Under these circumstances, afferent
arteriolar vasodilatation, increased renal perfusion and stress for
the glomeruli might translate into CKD within 12 months from the
operation.
An interesting consideration is whether miR-193b-3p might be
combined with other miRs to form a signature and whether this
would be more accurate in defining the prognosis of RN patients
than miR-193b-3p alone. We tested this hypothesis and we showed
that including multiple miRs in the predictive model does not
increase the performance of the model. Two potential explanations
might justify this observation: (a) there is collinearity in miR-193b-3p
and miR-363b-3p, miR-139b-5p and miR-365a-3p expression and
Table 2. Logistic regression analysis predicting development of postoperative chronic kidney disease in 71 patients treated with
radical nephrectomy for kidney cancer
Base model Model 1–miR193b Model 2–miR363b Model 3–miR139b Model 4–miR365a
Predictors
OR
(95% CI) P-value
OR
(95% CI) P-value
OR
(95% CI) P-value
OR
(95% CI) P-value
OR
(95% CI) P-value
microRNA – – 2.28 (1.42–4.14) 0.002 6.28 (1.42–42.4) 0.04 5.86 (1.82–24.6) 0.01 2.18 (1.30–4.19) 0.01
Age 1.04 (0.97–1.11) 0.3 1.02 (0.95–1.09) 0.6 1.03 (0.97–1.11) 0.4 1.02 (0.96–1.10) 0.5 1.03 (0.96–1.10) 0.5
Gender
Female Reference – Reference – Reference – Reference – Reference –
Male 6.07 (1.50–30.7) 0.02 4.69 (0.93–31.3) 0.08 5.25 (1.15–30.1) 0.04 6.47 (1.33–40.5) 0.03 7.27 (1.44–49.5) 0.03
Preoperative eGFR 0.93 (0.88–0.99) 0.02 0.91 (0.84–0.97) 0.01 0.93 (0.87–0.98) 0.02 0.91 (0.85–0.97) 0.01 0.91 (0.84–0.97) 0.01
Diabetes
No Reference – Reference – Reference – Reference – Reference –
Yes 2.48 (0.62–11.6) 0.2 6.86 (1.26–52.0) 0.04 4.38 (0.99–23.1) 0.06 4.94 (1.04–28.1) 0.05 5.32 (1.08–33.5) 0.05
Predictive
accuracy(%)
81 88 83 86 86
Abbreviations: CI¼ confidence interval; eGFR¼estimated glomerular fraction rate; OR¼odds ratio.
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Figure 3. Decision curve analysis plot comparing performance of a
predictive score including clinical variables (base model) alone or in
combination with specific miRs.
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as such there is no added predictive value in incorporating them
together; (b) the number of events (patients with eGFR derange-
ment at 12 months post RN) in our study is too limited to pick up
a difference in predictive value.
Although the identification of miR-193b-3p targets is beyond
the scope of our work, it is worth mentioning that several key
features of CKD, such as inflammatory cell infiltration, tubular cell
atrophy, mesangial cell hypertrophy and podocyte apoptosis, are
linked to transforming growth factor-b (TGF-b) pathway activa-
tion (Trionfini et al, 2015). Interestingly miR-193b-3p has been
shown to target TGF-b2- and TGFBR3 30-untranslated regions
suggesting a potential modulation of the pathway (Thiery, 2003;
Hou et al, 2015; Zhou et al, 2016).
Our data suggest that integrating miR-193b-3p expression
with clinical variables leads to a highly sensitive predictive model
for the determination of risk of comorbidities in patients
undergoing RN for RCC. Validation of our findings in prospective
cohorts of patients receiving RN and NSS for kidney cancer is
currently ongoing. Matched analysis of tissues, plasma and urine
will test the robustness of this marker and its applicability to
clinical practice.
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